In this article, we report the combined results of the phases Ib and II open-label, single-arm, multi-center studies on the clinical efficacy and safety of mefatinib in the first-line treatment of patients with advanced EGFR-mutant NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.